Research programme: eye disorders therapy - DebiopharmAlternative Names: DEBIO-88; UNIL 88
Latest Information Update: 09 Mar 2009
At a glance
- Originator Debiopharm
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Dry eyes
Most Recent Events
- 09 Mar 2009 Discontinued - Preclinical for Dry eyes in Switzerland (unspecified route)
- 27 Aug 2003 Preclinical trials in Dry eyes in Switzerland (unspecified route)